Showing 1491-1500 of 1564 results for "".
- Eye Specialist Works to Prevent Motor Vehicle Related Traumatic Eye Injurieshttps://modernod.com/news/eye-specialist-works-to-prevent-motor-vehicle-related-traumatic-eye-injuries/2476751/Within a 6-week period, Grady Memorial Hospital eye specialist Yousuf Khalifa, MD, witnessed an unusual set of traumatic eye injuries. Three patients, all riding with their windows down, suffered serious eye injuries when the glass in their exterior rear-facing side
- More Elderly Americans Dying From Fallshttps://modernod.com/news/more-elderly-americans-dying-from-falls/2476634/Death rates from falls are rising among elderly Americans and climbing fastest among seniors in their 90s, a US study suggests. Among all adults 75 and older, mortality from falls climbed 5.1% from 2000 to 2016, researchers report in JAMA. Death rates from falls rose the most—6.4%—among
- Ocular Therapeutix OTX-TP Intracanalicular Insert Fails to Meet Phase 3 Endpointhttps://modernod.com/news/ocular-therapeutix-otx-tp-intracanalicular-insert-fails-to-meet-phase-3-endpoint/2476598/Ocular Therapeutix’s intracanalicular insert failed to meet its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points, according to a company news release. OTX-TP is an intracanalicular insert that delivers a
- Zeiss Opens Cinema Lens Demo Center in Los Angeleshttps://modernod.com/news/zeiss-opens-cinema-lens-demo-center-in-los-angeles/2476584/For over 100 years, Zeiss has provided cinematography lenses to filmmakers at all levels. From their headquarters in Germany, each cine lens is designed and manufactured at the highest quality and exhibits the versatile look with neutral color rendition Zeiss is k
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr
- Proxy Advisory Firms Back Allergan in Battle with Dissident Shareholder Appaloosahttps://modernod.com/news/proxy-advisory-firms-back-allergan-in-battle-with-dissident-shareholder-appaloosa/2476472/Allergan said Monday that proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis have recommended that shareholders vote for all of the board’s proposals at its annual meeting on May 1, and against hedge fund Appaloosa’s proposal calling for the immediate separa
- NovaBay Pharmaceuticals Announces New Partner Pharmacy Programhttps://modernod.com/news/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/2476465/NovaBay Pharmaceuticals announced a new pharmacy partnering program in an effort to ensure all patients in the United States have reliable and affordable access to prescription Avenova, according to a company news release. NovaBay has recently added six new pharmacies as Avenova channel partners.
- Data Published on Acthar Gel Disease Status and Utilization Patterns in Uveitis Patientshttps://modernod.com/news/data-published-on-acthar-gel-disease-status-and-utilization-patterns-in-uveitis-patients/2476455/Mallinckrodt announced data from a retrospective chart review that analyzed physician assessments of 91 U.S. patients diagnosed with uveitis who had been treated with Acthar Gel (repository corticotropin injection) in the previous 12 months. All patients had completed
- Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DMEhttps://modernod.com/news/oxurion-nv-announces-full-enrollment-of-its-phase-2-trial-evaluating-combination-of-anti-plgf-thr-317-and-anti-vegf-ranibizumab-for-the-treatment-of-dme/2476439/Oxurion NV announced that all patients have been enrolled in its phase 2 trial evaluating its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of diabeti
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,